Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up (GlioConnect)

June 3, 2026 updated by: Centre Paul Strauss

Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of Diffusion Tensor Imaging (DTI) and Resting State Functional MRI (Rs-fMRI) to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up

The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms.

This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult patients
  • Patients with glioblastoma

  • Patients treated in the Nuclear Medicine & Molecular Imaging Department of the Strauss Institute for PET/MRI scans for:

    • Preoperative metabolic evaluation of a brain-expanding lesion

Exclusion Criteria:

  • Contraindications to MRI
  • Minor or incapacitated adult
  • Patient deprived of liberty
  • Patient under legal guardianship
  • Patient unable to consent
  • Pregnant or breastfeeding woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Patients with glioblastoma treated in the Department of Nuclear Medicine & Molecular Imaging
Other: 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences
fluorodeoxyglucose (Fluor18) (18F-FDG) PET/MRI with additional DTI and rs-fMRI sequences correlation with neuropsychological tests

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance before surgery
Time Frame: Before surgery
Before surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance after surgery
Time Frame: After surgery, through the study, i.e. for a maximum of 2 years
After surgery, through the study, i.e. for a maximum of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Paul Strauss

Investigators

  • Principal Investigator: Izzie-Jacques NAMER, MD, PhD, Institut public de cancérologie Strauss Europe

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 15, 2026

Primary Completion (Estimated)

September 15, 2030

Study Completion (Estimated)

September 15, 2030

Study Registration Dates

First Submitted

May 28, 2026

First Submitted That Met QC Criteria

June 3, 2026

First Posted (Actual)

June 4, 2026

Study Record Updates

Last Update Posted (Actual)

June 4, 2026

Last Update Submitted That Met QC Criteria

June 3, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-005
  • 2026-A01255-46 (Other Identifier: ID-RCB number)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe